Emerg Infect Dis. 2022 Nov;28(11):1-8. doi: 10.3201/eid2811.220415.
During 2020-2021, countries in Latin America and the Caribbean reported clinical emergence of carbapenemase-producing Enterobacterales that had not been previously characterized locally, increased prevalence of carbapenemases that had previously been detected, and co-production of multiple carbapenemases in some isolates. These increases were likely fueled by changes related to the COVID-19 pandemic, including empirical antibiotic use for potential COVID-19-related bacterial infections and healthcare limitations resulting from the rapid rise in COVID-19 cases. Strengthening antimicrobial resistance surveillance, epidemiologic research, and infection prevention and control programs and antimicrobial stewardship in clinical settings can help prevent emergence and transmission of carbapenemase-producing Enterobacterales.
在 2020-2021 年期间，拉丁美洲和加勒比国家报告了此前在当地尚未得到特征描述的产碳青霉烯酶肠杆菌科的临床出现，以前检测到的碳青霉烯酶的流行率增加，以及一些分离株中多种碳青霉烯酶的共同产生。这些增加可能是由与 COVID-19 大流行相关的变化所推动的，包括对可能与 COVID-19 相关的细菌感染进行经验性抗生素使用，以及 COVID-19 病例迅速增加导致的医疗保健限制。加强抗菌药物耐药性监测、流行病学研究以及临床环境中的感染预防和控制计划以及抗菌药物管理，可以帮助预防产碳青霉烯酶肠杆菌科的出现和传播。
